BIIB:NASDAQ
Biogen Inc
$248.52
arrow_upward
+1.88%(+4.59) 1D
Nov 6, 12:57:26 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$241.28
High
$249.04
Low
$240.00
Mkt. cap
36.74B
Avg. vol.
1.31M
Volume
307.82K
P/E ratio
106.38
52-wk high
$258.73
52-wk low
$151.83
EPS
$2.34
Beta
0.10
Shares outstanding
147.82M
No. of employees
8K
Open
$241.28
High
$249.04
Low
$240.00
Mkt. cap
36.74B
Avg. vol.
1.31M
Volume
307.82K
P/E ratio
106.38
52-wk high
$258.73
52-wk low
$151.83
EPS
$2.34
Beta
0.10
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
News Corp
·
20 hours ago
Biogen Inc. stock underperforms Thursday when compared to competitors
Zacks
·
23 hours ago
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Yahoo Finance
·
1 day ago
Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts
Yahoo Finance
·
1 day ago
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com